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Abstract
Background: A small but significant number of patients do not achieve CD4 T-cell counts .500cells/ml despite years of
suppressive cART. These patients remain at risk of AIDS and non-AIDS defining illnesses. The aim of this study was to
identify clinical factors associated with CD4 T-cell recovery following long-term cART.
Methods: Patients with the following inclusion criteria were selected from the Australian HIV Observational Database
(AHOD): cART as their first regimen initiated at CD4 T-cell count ,500cells/ml, HIV RNA,500copies/ml after 6 months of
cART and sustained for at least 12 months. The Cox proportional hazards model was used to identify determinants
associated with time to achieve CD4 T-cell counts .500cells/ml and .200cells/ml.
Results: 501 patients were eligible for inclusion from AHOD (n=2853). The median (IQR) age and baseline CD4 T-cell counts
were 39 (32–47) years and 236 (130–350) cells/ml, respectively. A major strength of this study is the long follow-up duration,
median (IQR)=6.5(3–10) years. Most patients (80%) achieved CD4 T-cell counts .500cells/ml, but in 8%, this took .5 years.
Among the patients who failed to reach a CD4 T-cell count .500cells/ml, 16% received cART for .10 years. In a multivariate
analysis, faster time to achieve a CD4 T-cell count .500cells/ml was associated with higher baseline CD4 T-cell counts
(p,0.001), younger age (p=0.019) and treatment initiation with a protease inhibitor (PI)-based regimen (vs. non-nucleoside
reverse transcriptase inhibitor, NNRTI; p=0.043). Factors associated with achieving CD4 T-cell counts .200cells/ml included
higher baseline CD4 T-cell count (p,0.001), not having a prior AIDS-defining illness (p=0.018) and higher baseline HIV RNA
(p,0.001).
Conclusion: The time taken to achieve a CD4 T-cell count .500cells/ml despite long-term cART is prolonged in a subset of
patients in AHOD. Starting cART early with a PI-based regimen (vs. NNRTI-based regimen) is associated with more rapid
recovery of a CD4 T-cell count .500cells/ml.
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Introduction
Most patients receiving suppressive cART will experience
significant increases in CD4 T-cell counts [1,2]. In most studies, the
pattern of change in CD4 T-cells following cART includes a rapid
increase in CD4 T-cells in the initial three months [3,4,5] which is
then followed bya slowerincrease in CD4 T-cellsin the subsequent 2–
3 years [4,6,7,8,9,10,11]. After 2–3 years of cART, changes in CD4
T-cells are less predictable. Some studies have reported sustained
increases in CD4 T-cell numbers up to 4 years following suppressive
cART [2,4,12], while others have reported a plateau beyond 3–4
years of cART [6,7,9,10,13]. In most patients, a plateau in CD4 T-
cells occurs within the normal range of CD4 T-cells [2], however, in a
small but significant number of patients CD4 T-cellsplateau below the
normal threshold of 500 cells/ml [1,14]. There is now growing
evidence that patients with CD4 T-cell counts ,500 cells/ml are at an
increased risk of AIDS and non-AIDS defining illnesses, despite
achieving complete viral suppression on cART [15,16,17,18].
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20713Multiplecohortstudies have assessed factors associated with CD4
T-cell recovery following cART and have found that older age
[1,4,6,8,13,19,20], lower baseline CD4 T-cell counts [3,6,8,12,
13,21], higher baseline HIV RNA [3,5,6,10,14,22,23,24], reduced
thymic function [25,26], increased levels of T-cell activation [27,28]
and detectable viremia while on treatment [3,4,6,12,22] are all
associated with reduced CD4 T-cell recovery. Many of these studies
have followed changes in CD4 T-cells in large cohorts [2,3,4,6,7,
9,12,13,21,22,24], but few studies have had prolonged follow-up
(.10 years) upon cART. The methodology used in these previous
studies was unable to distinguish subgroups of patients who take a
longer time to achieve CD4 T cells .500 cells/ml including those
initiating cART at low baseline CD4 T-cell counts [1], from those
who have plateaued at CD4 T-cell counts below 500 cells/mla n d
were unlikely to ever achieve this threshold. In addition, many prior
cohort studies included patients who were treatment experienced
prior to initiation of an effective cART regimen [1,6,11,21,24] and
restricted their analysis to only include patients who have
maintained viral suppression (defined differently from ,50 to
,1000 copies/ml) throughout follow-up [1,8,9,12,13,14]. Though
this approach measures the maximal capacity of immune recovery
in patients achieving the best possible virologic outcome with
cART, the findings from these studies may not be generalisable to
clinical practice where treatment responses may be variable and the
occurrence of virologic failure is unpredictable.
Given the clinical significance of achieving CD4 T-cell counts
.500 cells/ml in HIV-infected patients and the relative
limitations of some prior studies to identify patients who are
unlikely to reach this threshold especially following prolonged
treatment, the aim of this study was to identify factors associated
with the time taken to reach CD4 T-cell counts .500 cells/ml
following long-term cART in a large prospective clinic-based
cohort with prolonged follow-up.
Methods
Patient selection
The study population consisted of all patients enrolled in the
Australian HIV Observational Database (AHOD) at the time of
study, n=2853 (data updated March 2009). AHOD is an
observational database that collects demographic and HIV
treatment-related data from 27 sites consisting of general
practitioner services, sexual health clinics and hospitals throughout
Australia. The protocol for recruitment to AHOD was approved
by the institutional review board of each recruiting site (listed in
acknowledgements). All patients provided written informed
consent prior to AHOD recruitment and no further consent was
required for the conduct of this study. Details of this observational
cohort have been described elsewhere [29]. For this study, patients
were selected if they fulfilled the following inclusion criteria; men
or women aged at least 18 years and were ART naı ¨ve at
commencement of cART (defined as at least three antiretroviral
drugs), treatment was initiated at CD4 T-cell counts ,500 cells/ml
and patients achieved controlled viral suppression (defined as HIV
RNA,500 copies/ml) by 6 months of treatment initiation and
maintained viral suppression for at least 12 months.
Demographic and clinical parameters such as date of birth, sex,
hepatitis B and C status, HIV exposure category, diagnosis of
AIDS-defining illness (ADI) before cART initiation or at follow-
up, initial cART treatment regimen and all CD4 T-cell counts and
HIV RNA measures from cART initiation to the most recent data
available, were obtained from the March 2009 updated AHOD
database. Only CD4 T-cell counts with date matched HIV RNA
measures (within 1 month) were included in the analysis. The
closest matched CD4 T-cell count and HIV RNA measure prior
(within 1 year) to the date of cART commencement were
considered as baseline values. Patients who could not be assigned
a baseline CD4 T-cell count or HIV RNA measure by this
definition were excluded.
Statistical analysis
Survival analysis was used to identify determinants of CD4 T-
cell recovery following cART. Two clinically relevant end-points
were used to define the outcome, which were time taken to
achieve CD4 T-cells counts .500 cells/ml and .200 cells/ml
[30,31]. HIV RNA for all patients was included as a time-
dependent co-variate. This meant patients who were initially
aviremic (based on inclusion criteria) but subsequently developed
virological failure (two consecutive HIV RNA.500 copies/ml)
during follow-up remained in the analysis with appropriate
model adjustments for the influence of this parameter on the
outcome of interest. The Cox proportional univariate model was
used to initially identify candidate predictors of immune
reconstitution (p,0.2). These candidate variables were then
included in the Cox proportional multivariate model to identify
independent predictors of recovery. A p-value of ,0.05 in the
multivariate model was considered significant. Finally, Schoen-
feld residuals were used to assess the model for violations of the
proportional hazard assumptions and the model was accepted
only after no violations were shown to occur. Baseline CD4 T-
cell counts were square transformed in order to meet the
proportional hazard assumption in the analysis of time to achieve
CD4 T-cell counts .500 cells/ml. Comparisons of survival curves
of patients achieving CD4 T-cell counts .500 cells/mlw e r ed o n e
using the Log-rank test. All statistical analyses were performed
using STATA (version 10).
Results
Cohort characteristics
Five hundred and forty two (19%) patients fulfilled the inclusion
criteria and were selected from a study population of 2853. The
remainder of AHOD (n=2311) were excluded for the following
reasons; treatment experienced (n=1599; receiving mono or dual
therapy prior to cART), initiated treatment at CD4 T-cell counts
.500 cells/ml (n=424) and did not achieve controlled viremia by
6 months or sustain viral suppression for at least 12 months post-
cART (n=288). Of the 542 patients who fulfilled the inclusion
criteria, 41 patients were excluded because they had no matched
baseline CD4 T-cell/HIV RNA measure recorded in the database
or had no recorded baseline HIV RNA or follow up CD4 T-cell
counts (Figure 1). The remaining 501 patients were included in the
final analysis.
The majority of patients were males (94%) and the median
(IQR) age at cART initiation was 39 (32–47) years (Table 1).
The median (IQR) baseline CD4 T-cell count was 236 (130–
350) cells/ml and HIV RNA levels were 88 050 (25 875–
250 070) copies/ml. Sixty seven patients (13%) reported a
history of ADI prior to the commencement of cART while 23
patients (4.6%) developed 29 episodes of ADI on cART. These
episodes mostly occurred soon after cART initiation (median
(IQR)=4.5 (0.9–38.4) months). The median (IQR) follow-up
duration for the cohort was 6.5 (3.4–10.2) years and a median of
22 (IQR 12–34) pairs of matched CD4 T-cell and HIV RNA
measures per patient were included in the analysis. Nelfinavir
and indinavir were the most commonly used PIs (32% and 27%
of all PI regimens respectively). Most recruitment to AHOD was
before 2005, when these less potent PIs were being widely used
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and 55% of all NNRTI regimens).Thirty-four percent of patients
developed at least one episode of virological failure (VF) during
the follow-up period (5 and 10-year cumulative incidence (95%
CI) to the first episode of VF was 8.1/100 person-years (100 pyr)
(6.9–9.6) and 7.0/100 pyr (6.0–8.1) respectively). Among the
patients who developed episodes of VF, the median (IQR)
proportion of time spent with HIV RNA.500 copies/ml in
relation to the total duration of observation for each patient was
20 (7–38) %. Seventeen (3.4%) patients died during the follow-
up period (5 and 10-year cumulative incidence (95% CI) to
death was 0.2/100 pyr (0.1–0.6) and 0.5/100 pyr (0.3–0.8)
respectively).
Time taken to achieve CD4 T-cell counts .500 cells/ml
with long-term cART
The majority of patients (80%) eventually reached CD4 T-cell
counts .500 cells/ml and the median time taken to achieve this
was variable 1.2 (IQR=0.3–2.6) years. The majority of patients
(75%) who reached CD4 T-cell counts .500 cells/ml in the
cohort, achieved this threshold within 3 years of initiating cART
(Figure 2A) but a subset of patients took longer. These findings did
not change when the analysis was restricted to patients who
showed no evidence of virological failure (defined as 2 consecutive
HIV RNA.500 copies/ml) during follow-up, indicating that
slower reconstitution in these patients was unlikely to be due to loss
of virological control. As previously shown, stratification of the
time taken to achieve CD4 T-cell counts .500 cells/ml by baseline
CD4 T-cell counts (Figure 2B) showed that patients starting cART
at lower baseline CD4 T-cell categories took the longest times to
achieve counts .500 cells/ml [1].
A small subset of patients fail to achieve CD4 T-cell
counts .500 cells/ml despite long-term cART
Twenty percent of patients failed to achieve CD4 T-cell counts
.500 cells/ml. A similar proportion was found in the subset of
patients who achieved complete viral suppression throughout
follow-up (n=331, Figure 2A, characteristics described in Table 1).
Of the patients who failed to achieve CD4 T-cells .500 cells/ml
despite good virological control (n=67), 25% received at least 5
years of continuous suppressive therapy while 8% had been on
therapy for more than 10 years.
The 5-year cumulative incidence (95% CI) of not achieving
CD4 T-cell counts .500 cells/ml in patients initiating cART with
baseline CD4 T-cell counts of ,100, 101–200, 201–350 and
.350 cells/ml was 7.3/100 pyr (4.9–10.9), 10.2/100 pyr (6.9–
15.0), 5.8/100 pyr (3.4–10.1) and 1.5/100 pyr (0.2–10.7) respec-
tively (Figure 2B). The 5-year cumulative incidence (95% CI) of
patients not achieving counts .500 cells/ml was also higher among
those initiating cART with a NNRTI-based regimen (9.1/100 pyr
(6.8–12.1)) compared to patients initiating therapy with PI-based
regimens (boosted and unboosted; 4.0/100 pyr (2.3–7.0).
Predictors of time taken to achieve CD4 T-cell counts
.500 cells/ml and .200 cells/ml following long-term
cART
In a univariate analysis, factors associated with a more rapid
time to achieve CD4 T-cell counts .500 cells/ml included higher
baseline CD4 T-cells (square-transformed) (HR 1.14, 95% CI
1.13–1.16, p,0.001), younger age at cART initiation (HR 0.99
95% CI 0.98–0.99, p=0.023), no history of ADI prior to cART
initiation (HR 0.45, 95% CI 0.33–0.63, p,0.001) and earlier
calendar year of cART initiation (HR 0.77, 95% CI 0.61–0.97,
p=0.024) (Table 2). Although HIV exposure category, HIV RNA
measure as a time dependent covariate and treatment regimen
were not significant in the univariate model, these parameters
were still included in the multivariate model because they were
considered candidate predictors (p,0.2) based on our pre-defined
analysis strategy.
In the multivariate model, only higher baseline CD4 T-cell
counts (square-transformed) (HR 1.15, 95% CI 1.13–1.16,
p,0.001), younger age (HR 0.99, 95% CI 0.98–0.998,
p=0.019) and initiating treatment with a PI-based regimen
(boosted and unboosted) (vs NNRTI-based regimen) (HR 1.24,
95% CI 1.01–1.52, p=0.043) were significantly associated with
time taken to achieve CD4 T-cells .500 cells/ml. A prior history
of ADI and calendar year of starting cART were no longer
significant in the multivariate model.
In a subset of patients initiating cART at CD4 T-cell counts
,200 cells/ml, we assessed time taken to achieve CD4 T-cells
.200 cells/ml (n=196). The median (IQR) baseline CD4 T-cells
for these patients was 110 (50–170) cells/ml. In this multivariate
analysis, more rapid recovery to CD4 T-cell counts .200 cells/ml
was significantly associated with a history of ADI (HR 1.53, 95%
CI 1.07–2.18, p=0.018), higher baseline CD4 T-cell count (HR
4.53, 95% CI 3.32–6.19, p,0.001) and higher baseline HIV RNA
(HR 1.07, 95% CI 1.05–1.10, p,0.001) (Table 3).
Discussion
CD4 T-cell recovery following cART is variable and patients
who fail to achieve CD4 T-cell counts .500 cells/ml remain at risk
of AIDS and non-AIDS defining illnesses. In a large prospective
clinic-based cohort, we found that 80% of patients who achieved
early (12 months post-ART) virological control following cART,
achieved a CD4 T-cell count .500 cells/ml within a median
Figure 1. Patient disposition.
doi:10.1371/journal.pone.0020713.g001
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took significantly longer to eventually reach a CD4 T-cell count of
500 cells/ml, independent of whether there was complete viral
suppression throughout follow-up. Twenty percent of this clinic-
based cohort did not achieve CD4 T-cell counts .500 cells/ml
after a median follow-up of 6.5 years. In a multivariate analysis, we
found faster immune reconstitution to CD4 T-cell counts .500
cells/ml was significantly associated with higher baseline CD4 T-
cell counts, younger age and initiation of cART with a PI-based (vs
NNRTI-based) regimen.
Previous studies have used multiple approaches to quantify CD4
T-cell recovery following cART. Unlike most studies which have
assessed CD4 T-cell recovery as the rate of CD4 T-cell increase or
an absolute change in CD4 T-cell count, we quantified CD4 T-cell
recovery by the time taken to achieve a CD4 T-cell count .500
cells and .200 cells/ml. We believe this approach was more robust
because it accounted for both the differences in rate, pattern and
extent of immune reconstitution that patients receiving cART may
experience especially following long-term therapy. Additionally,
this approach eliminated the need to establish a consistent pattern
of CD4 T-cell increase with time, which is required when more
complex regression models are used to assess CD4 T-cell recovery
[9]. Regression models however, do have the advantage of
estimating subject specific and average CD4 T-cell gains in the
cohort and unlike the Kaplan Meier approach is less affected by
the biases that may be inferred due to the loss of patients during
follow-up.
We found that the time taken to achieve CD4 T-cell counts
.500cells/ml was highly variable, with a small but significant
subset of patients experiencing prolonged periods (.5 years) with
a CD4 T-cell count ,500 cells/ml. As expected this was most
commonly observed in patients who initiated cART at CD4 T-cell
counts ,100 cells/ml. Many other studies have demonstrated poor
CD4 T-cell recovery in patients initiating cART at low CD4 T-cell
counts [1,3,13,21] or those experiencing poor virological control
[6,22,32,33] following cART. We surprisingly found that in our
cohort, loss of virological control during treatment did not
significantly alter the distribution of time taken to achieve counts
.500cells/ml, nor did it influence the proportion of patients
achieving this threshold. This observation may have been
influenced by the fact that our study excluded patients with poor
virological response in the first 12 months following cART, a time
period when CD4 T-cell increases are greatest and the occurrence
of virological failure at this early phase may have the strongest
Table 1. Demographic and clinical characteristics of patients from AHOD who met the inclusion criteria for this study.
Patient characteristics All patients (n=501) Median (IQR)
Patients with complete viral
suppression (n=331) Median (IQR)
Gender
- Male, n (%) 470 (93.8%) 310 (93.7%)
- Female, n (%) 30 (6.0%) 21 (6.3%)
- Transgender, n (%) 1 (0.2%) 0
Age at cART initiation (years) 39 (32.0–47.0) 41 (34.0–48.0)
Positive hepatitis C virus antibody, n (%) 41 (8.2%) 23 (6.9%)
Positive hepatitis B surface antigen, n (%) 26 (5.2%) 14 (4.2%)
Baseline CD4+ T-cell count (cells/ml) 238 (130–350) 234 (130–340)
Baseline HIV RNA (copies/ml) 87 800 (25 650–248 450) 85 600 (23 000–220 000)
HIV exposure category
- MSM 376 (75.1%) 247 (74.8%)
- Heterosexual contact 66 (13.1%) 44 (13.3%)
- Others* 59 (11.8%) 40 (13.0%)
Follow-up duration, years 6.5 (3.4–10.2) 5.0 (2.7–9.3)
History of AIDS defining illness, n (%) 67 (13.3%) 44 (13.3%)
Death during follow-up, n (%)
- AIDS/HIV-related 4 (0.8%) 2 (0.6%)
- Not HIV-related 9 (1.8%) 6 (1.8%)
- Unknown 4 (0.8%) 1 (0.3%)
cART regimen at baseline, n (%)
-NNRTI-based 293 (58.4%) 202 (60.8%)
-PI-based 179 (35.7%) 106 (31.9%)
-Triple NRTI-based 20 (4.2%) 15 (4.8%)
-Others 9 (1.8%) 8 (2.4%)
All parameters are median (IQR) unless otherwise stated.
cART-combination Antiretroviral therapy; MSM – men who have sex with men; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor (boosted
and unboosted); NRTI – nucleoside reverse transcriptase inhibitor.
*Others included injecting drug use, transfusion and unrecorded.
PIs included Atazanavir (boosted and unboosted) (5%), Lopinavir/Ritonavir (11%), Indinavir (boosted and unboosted) (32%), Nelfinavir (27%), Ritonavir (10%), Saquinavir
(boosted and unboosted) (13%), Tipranavir (1%), Fosamprenavir (1%); NNRTIs included Delavirdine (1%), Efavirenz (44%), Nevirapine(55%);
doi:10.1371/journal.pone.0020713.t001
Clinical Predictors of Immune Recovery
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20713negative impact on subsequent rates of CD4 T-cell increase [32].
Additionally, the median proportion of time spent with HIV RNA
.500 copies/ml over the entire observation period among
patients experiencing virological failure was short in this study.
Other studies have described higher thresholds of detectable
viremia before a significant negative influence on CD4 T-cell
recovery was found to occur [6].
Even among patients who experienced continued viral suppres-
sion throughout follow-up, there was a subset of patients who took
significantly longer to achieve CD4 T-cells .500 cells/ml. Similar
to that described in other studies [1,13,14], we also found a small
subset of patients failed to achieve counts .500 cells/ml despite
receiving long-term suppressive cART.
We found baseline CD4 T-cell count was independently
associated with the time taken to reach both CD4 counts .500
cells/ml and .200 cells/ml in both multivariate analyses.
Numerous studies with long-term follow-up have also reported
similar findings [3,4,6,8,13,21]. Patients starting therapy at low
CD4 T-cell nadir may experience immunologic dysfunction that
may impede their capacity to achieve robust CD4 T-cell increases
with cART. Longitudinal studies have shown that patients starting
therapy at low CD4 T-cell nadir experience a skewed distribution
of CD4 T cell subsets with significantly lower naı ¨ve and higher
effector cell subsets compared to patients starting treatment at
higher CD4 T-cell nadir (counts .350cells/ml) [34,35]. This
abnormality persists following CD4 T-cell recovery even after
prolonged (median 6 years) suppressive therapy [35]. The greater
turnover of effector cells compared to the longer-lived naı ¨ve cells
may in part contribute to the slower net increase in CD4 T-cell
numbers experienced by these patients following treatment.
Additionally numerous studies have also found that poor CD4
T-cell recovery following suppressive cART is associated with
increased immune activation (measured by soluble and T-cell
activation markers) and T-cell apoptosis [36,37,38,39,40]. Taken
together, these data imply that in patients starting cART at low
baseline CD4 T-cell counts, numerous pathogenic mechanisms
may collectively work to slow their increase in CD4 T-cell
numbers and prolong their risk of acquiring AIDS and non-AIDS
defining illnesses.
Current HIV treatment guidelines are mixed on when to initiate
cART with some guidelines recommending initiation at ,350
cells/ml [41,42] and others recommending initiation at ,500
cells/ml [43,44]. Our data demonstrated that a significantly higher
proportion of patients initiating treatment at counts .350 cells/ml
achieved counts .500 cells/ml and that these patients spent
shorter periods below this threshold following cART compared to
patients starting therapy at CD4 T-cell counts between 200–350
cells/ml. These data provide further support for earlier initiation of
cART.
As previously reported [1,4,6,8,13,19,20], we found younger
age to be a significant predictor of faster reconstitution to counts
.500 cells/ml. The favourable immune response associated with
starting cART at a younger age is probably related to the T-cell
regenerative capacity of these patients compared to older patients
in whom physiological involution of the thymus may limit their
ability to produce naı ¨ve T-cells [45,46,47,48]. Younger age has
also been associated with better CD4 T-cell recovery in other
lymphopenic conditions including following hematopoetic stem
cell transplantation and chemotherapy [49,50,51]. In this study,
age was only significantly associated with time to reach a CD4 T-
cell count .500 cells/ml and not .200 cells/ml. This was
consistent with the findings from other studies [3,12,23,45] where
age positively influenced long-term immune reconstitution and not
early recovery (,3 months) where increases in CD4 T-cell
numbers immediately following cART initiation was generally
associated with the redistribution of T-cells from lymphoid tissue
[34,52] rather than de novo T-cell production.
We surprisingly found that patients initiating cART with a PI-
based regimen (boosted and unboosted) achieved faster reconsti-
tution to CD4 T-cell counts .500 cells/ml when compared to
patients receiving NNRTI-based regimens. This association
remained significant even when calendar year was included in
the multivariate model to adjust for the historical preference of
initiating patients with PI-based regimens during the early cART
era (data not shown). We also explored if treatment switches from
the anchor regimen during follow-up had an influence on the time
to reach CD4 T-cell counts .500 cells/ul by including treatment
regimen as a time dependent co-variate in the model but did not
find a significant association (data not shown), consistent with
another recent study [53]. The lack of association between
subsequent treatment switch and CD4 T-cell recovery may be
because the majority of patients (86.5%) who achieved counts
.500 cells/ml in this cohort did so while receiving their initial
treatment regimen. The influence of treatment regimen on the
capacity of long-term CD4 T-cell reconstitution is still unclear.
Multiple studies have reported that patients receiving PI-based
Figure 2. Kaplan-Meier plots showing time taken to achieve
CD4 T-cell counts .500 cells/ml following cART initiation.
Kaplan-Meier plots showing time taken to achieve CD4 counts
.500cells/ml among (A) patients in the total cohort (n=501) and
patients with no evidence of virological failure (VF) (2 consecutive HIV
RNA.500copies/ml) throughout follow-up (n=331) and (B) all patients
(n=501) stratified by baseline CD4 T-cell counts (,100cells/ml, n=99;
101–200cells/ml, n=107; 201–350cells/ml, n=172; .350cells/ml, n=123).
Comparisons of survival curves were done using the Log-rank test
(STATA 10.0).
doi:10.1371/journal.pone.0020713.g002
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59,60] while others have not confirmed these observations
[61,62,63,64,65,66]. Protease inhibitors have been described to
exert anti-apoptotic [67] and restore T-cell proliferative responses
[68] independent of their antiretroviral activity, however these
findings have also been inconsistent [69]. The positive association
of PI-based regimen and more rapid CD4 T-cell recovery in our
study should be interpreted with caution because this is an
observational study of a clinic-based cohort where the choice of
treatment offered to patients may not have been random and may
have been influenced by multiple factors including degree of
immunosuppression at the time of initiation of cART and viral
mutation patterns that has not been adjusted for in our statistical
analysis.
Apart from baseline CD4 T-cell counts, the factors associated
with time to reach CD4 T-cell counts .200 cells/ml were found to
be different from those associated with recovery to .500 cells/ml.
We found that patients with a history of an ADI and higher
baseline HIV RNA were associated with faster recovery to counts
.200 cells/ml consistent with other reports [3,5,6,12,14,22,23,24].
HIV-infected patients with profound immune-suppression may
experience greater sequestration of CD4 T-cells into lymphoid
tissues which are then released into the peripheral circulation
following cART-induced viral suppression [45,52,70,71]. This
might potentially explain the faster time taken to achieve CD4 T-
cell counts .200 cells/ml among patients with higher baseline
HIV RNA and ADI in this study.
We did not find an association between hepatitis C serostatus
and CD4 T-cell recovery as has been previously described in some
[22,61,72,73] but not all [74,75,76] studies. This could be due to
the small number of patients (,10%) with HCV in this study.
Additionally, HCV seropositivity is strongly associated with active
injecting drug use [72] which in this study only accounted for a
minority in the HIV-risk transmission group.
Table 2. Predictors of time taken to achieve CD4 T-cells .500 cells/ml (n=501).
Variable
Univariate Hazard
Ratio (95% CI) p-value
Multivariate Hazard
Ratio (95% CI) p-value
CD4 T-cell baseline (square-transformed), per 100 units
# 1.14 (1.13–1.16) ,0.001 1.15 (1.13–1.16) ,0.001
Baseline HIV RNA, per 100 000 copies/ml 0.99 (0.97–1.02) 0.606
HIV RNA per 100 000 copies/ml (time dependent covariate) 0.33 (0.09–1.12) 0.074
Age at cART initiation, years 0.99 (0.98–0.99) 0.023 0.99 (0.98–0.998) 0.019
Initial cART regimen
-NNRTI regimen* - -
-PI regimen 1.16 (0.94–1.42) 0.158 1.24 (1.01–1.52) 0.043
-Triple NRTI regimen 1.10 (0.66–1.83) 0.716 1.08 (0.65–1.81) 0.763
-Others 1.40 (0.69–2.84) 0.349 0.77 (0.38–1.57) 0.476
Calendar year of starting cART
-1997–1999* -
-2000–2004 0.77 (0.61–0.97) 0.024
-$2005 0.93 (0.70–1.23) 0.607
HIV exposure category
-MSM* -
-Heterosexual contact 0.74 (0.54–1.00) 0.051
-Other** 0.92 (0.67–1.27) 0.610
HBsAg positive
-Yes 0.88 (0.56–1.38) 0.563
-No* -
HCV Ab positive
-Yes 0.81 (0.56–1.17) 0.256
-No* -
Gender
-Male 0.90 (0.61–1.33) 0.604
-Female* -
History of ADI
-Yes 0.45 (0.33–0.63) ,0.001
-No* -
*Reference category.
**Others included injecting drug use, transfusion and unrecorded.
#For every 100-unit increase in square transformed baseline CD4 T-cell counts, the hazard of achieving a CD4 T-cell threshold of .500cells/ml increased by 15%.
cART-combination Antiretroviral therapy; MSM – men who have sex with men; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor (boosted
and unboosted) ; NRTI – nucleoside reverse transcriptase inhibitor; ADI – AIDS-defining illness; HBsAg – hepatitis B surface antigen; HCV Ab – hepatitis C antibody.
doi:10.1371/journal.pone.0020713.t002
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follow-up and this characteristic of the cohort allowed us to
distinguish patients with a slow recovery to CD4 T-cell counts
.500 cells/ml from those who are unlikely to ever achieve this
threshold. However, there were several important limitations too.
First, we defined viral suppression as an HIV RNA,500 copies/
ml instead of the more sensitive cut-off of ,50 copies/ml [2,77].
We did this because not all patients had testing with the more
sensitive HIV RNA assays in the early cART era. Second, we used
the time to reach a defined event of CD4 T-cells .500 cells/mlo r
.200 cells/ml which could potentially overestimate the number of
patients achieving these events given the wide fluctuations in CD4
T-cell counts that may occur in a patient and it is possible that
these patients may not consistently maintain CD4 T-cell counts
above these thresholds over the long term. As previously reported
[1,53], we found that the likelihood of a patient achieving a
threshold of .500 cells/mlo r.200 cells/ml and then experiencing
a decline in CD4 T-cell count was low. The majority of patients
who reached these thresholds maintained these levels of CD4 T-
cell reconstitution unless they experienced episodes of virological
failure. In patients without episodes of virological failure, only 4
patients (1.5%) who reached counts .500 cells/ml experienced a
subsequent decline in CD4 T-cell numbers without any evidence
of increase in HIV RNA while all patients who reached CD4 T-
cell counts .200 cells/ml subsequently maintained counts above
this threshold. Finally, this was an observational clinic-based
cohort and therefore our results may have been biased towards
patients who reliably attend physician appointments.
In summary, we found that the majority of patients in a clinic-
based observational cohort eventually achieved CD4 T-cell counts
.500 cells/ml but in 8% of patients this took over 5 years. Our
findings support the initiation of cART early as both younger age
and higher baseline CD4 T-cell counts were associated with faster
CD4 T-cell recovery to counts .500 cells/ml. The small number
of patients who failed to achieve counts .500cells/ml despite
receiving long-term suppressive cART suggest that current
standard cART regimens alone may not be sufficient to achieve
complete CD4 T-cell recovery in some patients. In these patients,
Table 3. Predictors of time taken to achieve CD4 T-cells .200 cells/ml (n=196).
Variable
Univariate Hazard
Ratio (95% CI) p-value
Multivariate
Hazard Ratio (95% CI) p-value
CD4 T-cell baseline, per 100 cells/ml 3.35 (2.55–4.40) ,0.001 4.53 (3.32–6.19) ,0.001
Baseline HIV RNA, per 100 000 copies/ml 1.04 (1.01–1.07) 0.012 1.07 (1.05–1.10) ,0.001
HIV RNA, per 100 000 copies/ml (time dependent covariate) 0.80 (0.46–1.39) 0.425
Age at cART initiation, years 0.99 (0.98–1.01) 0.271
Initial cART regimen
-NNRTI regimen* -
-PI regimen 1.07 (0.79–1.44) 0.666
-Triple NRTI regimen 0.51 (0.23–1.12) 0.093
Calendar year of starting cART
-1997–1999* -
-2000–2004 0.96 (0.70–1.32) 0.802
-$2005 1.24 (0.84–1.83) 0.275
HIV exposure category
-MSM* -
-Heterosexual contact 0.71 (0.47–1.06) 0.091
-Others** 0.64 (0.41–1.01) 0.055
HBsAg positive
-Yes 1.11 (0.61–2.00) 0.738
-No* -
HCV Ab positive
-Yes 1.04 (0.64–1.68) 0.868
-No* -
Gender
-Male 0.95 (0.53–1.71) 0.865
-Female* -
History of ADI
-Yes 0.79 (0.58–1.08) 0.138 1.53 (1.08–2.18) 0.018
-No* -
*Reference category.
**Others included injecting drug use, transfusion and unrecorded.
cART-combination Antiretroviral therapy; MSM – men who have sex with men; NNRTI – non-nucleoside reverse transcriptase inhibitor; PI – protease inhibitor (boosted
and unboosted) ; NRTI – nucleoside reverse transcriptase inhibitor; ADI – AIDS-defining illness; HBsAg – hepatitis B surface antigen; HCV Ab – hepatitis C antibody.
doi:10.1371/journal.pone.0020713.t003
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explored.
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